2017 News | Events | Industry Updates

18 September 2017

Carol Austin, Associate Director of Discovery, who currently manages two Cypralis Innovate UK projects, said ‘Selcia’s unique expertise in the area of peptidyl prolyl isomerase assay development and screening should enable Cypralis to achieve the milestones for this third challenging project. We look forward to continuing to support Cypralis in achieving the goals of this new Innovate UK Feasibility award’.

Cypralis issued a press release on 18th September 2017; follow this link for the full version:

10 February 2017

Selcia, with colleagues from Cypralis and Gilead Sciences Inc., have published in the Journal of Medicinal Chemistry a novel strategy of structural simplification of a natural product to generate synthetically tractable cyclophilin inhibitors for the treatment of HCV.